Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus SYNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus SYNACORT.
ASMANEX HFA vs SYNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Synthetic corticosteroid with potent glucocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
100 mg intravenously every 8 hours for 24 hours, then 50 mg intravenously every 8 hours for 48 hours, followed by 25 mg intravenously every 8 hours for 72 hours.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Terminal elimination half-life is 2.5–3.5 hours; clinically, this short half-life requires multiple daily dosing for sustained effects.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Primarily renal (80% as metabolites, 20% unchanged); minor biliary/fecal (<5%).
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid